Egetis Therapeutics AB (publ) (STO:EGTX)

Egetis Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-343.6	-326.9	-193.8	-104.5	-178.02
Depreciation & Amortization	3.5	3.6	2.7	2.5	0.4
Stock-Based Compensation	14.7	8	8.8	1.2	0.56
Other Operating Activities	8.9	6	-2.1	-1.1	0.38
Change in Accounts Receivable	13.4	-22.9	-10.7	3.1	16.43
Change in Other Net Operating Assets	75.2	53.8	21.6	-31.3	25.62
Operating Cash Flow	-227.9	-278.4	-173.5	-130.1	-134.64
Capital Expenditures	-	-	-	-0.2	-0.02
Cash Acquisitions	-1.2	-	-1.7	-5	-59.52
Investment in Securities	-	-	-	-0.8	-
Other Investing Activities	-	-	-	-	0
Investing Cash Flow	-1.2	-	-1.7	-6	-59.54
Long-Term Debt Issued	-	108.8	-	-	-
Long-Term Debt Repaid	-10.2	-5.6	-9.1	-8.9	-0.22
Net Debt Issued (Repaid)	-10.2	103.2	-9.1	-8.9	-0.22
Issuance of Common Stock	301.5	381.9	177.4	-	250.75
Repurchase of Common Stock	-1.5	-	-	-	-
Other Financing Activities	-18.9	-26.2	-12.6	-	-22.13
Financing Cash Flow	270.9	458.9	155.7	-8.9	228.41
Foreign Exchange Rate Adjustments	5.8	-4.8	3.2	1.1	-1.47
Net Cash Flow	47.6	175.7	-16.3	-143.9	32.75
Free Cash Flow	-227.9	-278.4	-173.5	-130.3	-134.66
Free Cash Flow Margin	-494.36%	-483.33%	-767.70%	-341.10%	-331.18%
Free Cash Flow Per Share	-0.73	-1.07	-0.89	-0.72	-2.00
Cash Interest Paid	8.5	4.1	0.1	-	0
Cash Income Tax Paid	0.3	0.1	-	-	-
Levered Free Cash Flow	-105.33	-159.79	-112.39	-90.55	-62.98
Unlevered Free Cash Flow	-94.33	-157.16	-112.33	-90.43	-62.98
Change in Net Working Capital	-88.6	-25.8	0.7	28.18	-46.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.